Central Nervous System Biomarker Market Analysis By Application, By End User, By Type, Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: Jan 31, 2016

Key findings


The Global Central Nervous System Biomarkers Market is expected to grow at the CAGR of 20% during 2015-2022 and it estimated to be $XX billion by 2022. The Global Central Nervous System Biomarkers Market is majorly driven by the development in proteomics, genomics and imaging system has increased demand for CNS biomarker.

Growing prevalence of life style oriented diseases and government support for research and development is driving the market. Global adoption of CNS biomarkers in developed and emerging economies has created huge scope in the market. Global Central Nervous System Biomarkers Market by applications such as diagnostic development, drug discovery and development, personalized medicine, disease risk assessment and so on is creating huge scope in Global Central Nervous System Biomarkers Market. The most common reason why companies are entering Global Central Nervous System Biomarkers Market is the significant development in personalized medicines and drug discovery & development domains.

Global Central Nervous System Biomarkers Market by type such as safety biomarker, efficacy biomarker, predictive biomarker, prognostic biomarker and so on enables the companies to explore more in the market. As a result there is significant rise in revenues compared to past. It enables the Global Central Nervous System Biomarkers Market to attract other major players to enter into the market in coming years. Emerging economies such as India, China, Japan and Korea are expected to contribute significantly in the next few years.

The Global Central Nervous System Biomarkers Market companies such as Abastar MDX Inc, Thermo fisher scientific, Abiant Inc, EKFdiagnostics holdings inc, Enzo biochem inc, Acumen pharmaceuticals Inc, Adlyfe Inc, Alseres pharmaceuticals Inc, Apitope international, Aposense, Applied neurosolutions Inc, Avacta group plc, Merc & co. Inc, Avid radiopharmaceuticals Inc, Banyan biomarkers, Diagenic ASA, Exonhit therapeutics are constantly focusing on innovation and technological advancement. Also with increasing competition in the market companies are focusing on mergers and acquisition, partnership, collaboration, expansion and launching of new products.


Market segment insight


The application market for Global Central Nervous System Biomarkers Market is segmented on the basis of application, type, end user and geography. The major segment in Global Central Nervous System Biomarkers Market is by application which includes diagnostic development, drug discovery and development, personalized medicine, disease risk assessment and so on.


Regional insight


Globally, North America dominates the Global Central Nervous System Biomarkers Market with high investments from manufacturers due to growing demand. However, North America is expected to contribute more than 50% market share followed by Europe and APAC. Both the regions are expected to create significant opportunities for the growth of the market during the forecasted years. Growing demand of Global Central Nervous System Biomarkers Market in emerging economies are the major drivers.


Competitive insight


The key players in the Global Central Nervous System Biomarkers Market include as Abastar MDX Inc, Thermo fisher scientific, Abiant Inc, EKFdiagnostics holdings Inc, Enzo biochem Inc, Acumen pharmaceuticals Inc, Adlyfe Inc, Alseres pharmaceuticals Inc, Apitope international, Aposense, Applied neurosolutions Inc, Avacta group plc, Merc & co. Inc, Avid radiopharmaceuticals Inc, Banyan biomarkers, Diagenic ASA, Exonhit therapeutics, Genenews ltd, Glycominds ltd, Great lakes neurotechnologies, Innogenetics biological, innovative neurotechnologies and so on. Mergers and Acquisition is the key strategy adopted in the Global Central Nervous System Biomarkers Market to stay competitive. Also companies are adopting mergers and acquisition as strategy to stay competitive and partnerships to reach masses and explore the market.


Reasons for buying the report

 

  • This report provides a detailed study of current trends in the Global Central Nervous System Biomarkers Market, key growth drivers, and restraints.
  • It provides market forecast for the next 7 years (2015-2022) assessed on the basis of market growth.
  • The report also includes analysis of recent technological developments in the Global Central Nervous System Biomarkers Market, analysis of key market players and the key winning strategy adopted and predictive analysis.
  • The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
  • The report tracks and analyse the changing market dynamics.
  • The report also talks about emerging opportunities in the market and the future impact of major drivers and restraints of the market.
  • The report also provides extensive analysis with respect to key product segments.
  • The analysis in the report will help in making effective business decisions.
  • It provides analysis through distinctive graphs and charts and analyses strengths, weakness, opportunities and threats of major market players.

1. METHODOLOGY & SCOPE 9

    1.1. Research Methodology 9
    1.2. Research Scope & Assumptions 9
    1.3. List of Data Sources 9


2. EXECUTIVE SUMMARY 10

    2.1. GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET summary & key buying criteria 10
    2.2. GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET outlook 10


3. MARKET SEGMENTATION 11

    3.1. Market size and growth prospects 2012-2022 11
    3.2. GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET value chain analysis 11
    3.3. Vendor Landscape 11


4. GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET 12

    4.1. Market driver analysis 12
        4.1.1. DEVELOPMENT IN PROTEOMICS, GENOMICS AND IMAGING SYSTEM HAS INCREASED DEMAND FOR CNS BIOMARKER 12
       4.1.2. FUNDING FROM GOVERNMENT AND PRIVATE PLAYERS TO BOOST CNS BIOMARKER MARKET 12
       4.1.3. Growth in life style oriented diseases 12
       4.1.4. Growth in government and private funding in CNS biomarker market 12
       4.1.5. FDA APPROVALS TO BOOST THE MARKET 12
    4.2. Market restraint analysis 12
        4.2.1. HIGH COST OF CNS BIOMARKER TEST AND DIAGNOSTICS 12
        4.2.2. REIMBURSEMENT ISSUES AFFECTING THE CNS BIOMARKER MARKET 12
        4.3.1. INCREASING ADOPTION OF PERSONALIZED MEDICINES 12
        4.3.2. UNTAPPED APAC REGION HAS HUGE SCOPE FOR CNS BIOMARKER MARKET 12
        4.3.3. GLOBAL INCREASE IN AGING POPULATION HAS CREATED HUGE SCOPE FOR CNS BIOMARKER MARKET 12
        4.3.4. FAVORABLE GOVERNMENT POLICIES AND SUPPORT FOR CNS BIOMARKERS 12


5. INDUSTRY ANALYSIS – PORTER’S 13

    5.1. GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET– PESTEL analysis 13


6. GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET BY APPLICATION 2012-2022 ($ BILLION) 14


 7. GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET BY END USER 2012-2022 ($ BILLION) 15


8. GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET BY TYPE 2012-2022 ($ BILLION) 16


9. GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET REGIONAL OUTLOOK 2012-2022 ($ BILLION) 17

    9.1. North America

        9.1.1. North America market estimates and forecast 2012-2022 ($ billion) 17
        9.1.2. North America market estimates and forecast by region 2012-2022 ($ billion) 17
        9.1.3. North America market estimates and forecast by application 2012-2022 ($ billion) 17
            9.1.3.1. U.S. 17
                9.1.3.1.1. U.S. market estimates and forecast 2012-2022 ($ billion) 17
                9.1.3.1.2. U.S. market estimates and forecast by application 2012-2022 ($ billion) 17
            9.1.3.2. Canada 17
                9.1.3.2.1. Canada market estimates and forecast 2012-2022 ($ billion) 17
                9.1.3.2.2. Canada market estimates and forecast by application 2012-2022 ($ billion) 17
            9.1.3.3. Mexico 17
                9.1.3.3.1. Mexico market estimates and forecast 2012-2022 ($ billion) 17
                9.1.3.3.2. Mexico market estimates and forecast by application 2012-2022 ($ billion) 17
            9.1.3.4. Europe 17
        9.1.4. Europe market estimates and forecast 2012-2022 ($ billion) 18
        9.1.5. Europe market estimates and forecast by region 2012-2022 ($ billion) 18
        9.1.6. Europe market estimates and forecast by application 2012-2022 ($ billion) 18
            9.1.6.1. Germany 18
                9.1.6.1.1. Germany market estimates and forecast 2012-2022 ($ billion) 18
                 9.1.6.1.2. Germany market estimates and forecast by application 2012-2022 ($ billion) 18
            9.1.6.2. UK 18
                9.1.6.2.1. UK market estimates and forecast 2012-2022 ($ billion) 18
                9.1.6.2.2. market estimates and forecast by application 2012-2022 ($ billion) 18
            9.1.6.3. Russia 18
                9.1.6.3.1. Russia market estimates and forecast 2012-2022 ($ billion) 18
                9.1.6.3.2. Russia market estimates and forecast by application 2012-2022 ($ billion) 18
            9.1.6.4. Asia Pacific 18
        9.1.7. Asia Pacific market estimates and forecast 2012-2022 ($ billion) 18
        9.1.8. Asia Pacific market estimates and forecast by region 2012-2022 ($ billion) 18
        9.1.9. Asia Pacific market estimates and forecast by application 2012-2022 ($ billion) 18
            9.1.9.1. China 18
                9.1.9.1.1. China market estimates and forecast 2012-2022 ($ billion) 19
                9.1.9.1.2. China market estimates and forecast by application 2012-2022 ($ billion) 19
            9.1.9.2. India 19
            9.1.9.2.1. India market estimates and forecast 2012-2022 ($ billion) 19
            9.1.9.2.2. India market estimates and forecast by application 2012-2022 ($ billion) 19
        9.1.9.3. South Korea 19
            9.1.9.3.1. South Korea market estimates and forecast 2012-2022 ($ billion) 19
            9.1.9.3.2. South Korea market estimates and forecast by application 2012-2022 ($ billion) 19
        9.1.9.4. Middle East & Africa 19
            9.1.9.4.1. Middle East & Africa market estimates and forecast 2012-2022 ($ billion) 19
            9.1.9.4.2. Middle East & Africa market estimates and forecast by application 2012-2022 ($ billion) 19
    9.2. Central & South America 19
        9.2.1. Central & South America market estimates and forecast 2012-2022 ($ billion) 19
        9.2.2. Central & South America market estimates and forecast by application 2012-2022 ($ billion) 19
            9.2.2.1. Brazil 19
                9.2.2.1.1. Brazil market estimates and forecast 2012-2022 ($ billion) 19
                9.2.2.1.2. Brazil market estimates and forecast by application 2012-2022 ($ billion) 19


10. COMPETITIVE LANDSCAPE 20

    10.2. THERMO FISHER SCIENTIFIC 21
    10.3. Abiant Inc 21
    10.4. Enzo biochem inc 21
        10.4.1. Company Overview 21
        10.4.2. Financial Performance 21
        10.4.3. Product Benchmarking 21
        10.4.4. Strategic Initiatives 21
    10.5. Acumen pharmaceuticals Inc 21
        10.5.1. Company Overview 21
        10.5.2. Financial Performance 21
        10.5.3. Product Benchmarking 21
        10.5.4. Strategic Initiatives 21
    10.6. Adlyfe Inc 22
        10.6.1. Company Overview 22
        10.6.2. Financial Performance 22
        10.6.3. Product Benchmarking 22
        10.6.4. Strategic Initiatives 22
     10.7. Alseres pharmaceuticals Inc 22
        10.7.1. Company Overview 22
        10.7.2. Financial Performance 22
        10.7.3. Product Benchmarking 22
        10.7.4. Strategic Initiatives 22
    10.8. Apitope international 22
        10.8.1. Company Overview 22
        10.8.2. Financial Performance 22
        10.8.3. Product Benchmarking 22
        10.8.4. Strategic Initiatives 22
    10.9. Aposense 22
        10.9.1. Company Overview 22
        10.9.2. Financial Performance 22
        10.9.3. Product Benchmarking 22
        10.9.4. Strategic Initiatives 22
    10.10. Applied neurosolutions Inc 22
         10.10.1. Company Overview 22
         10.10.2. Financial Performance 22
         10.10.3. Product Benchmarking 22
         10.10.4. Strategic Initiatives 22
    10.11. Avacta group plc 22
         10.11.1. Company Overview 22
         10.11.2. Financial Performance 23
         10.11.3. Product Benchmarking 23
         10.12.1. Company Overview 23
         10.12.2. Financial Performance 23
         10.12.3. Product Benchmarking 23
         10.13.1. Company Overview 23
         10.13.2. Financial Performance 23
         10.13.3. Product Benchmarking 23
         10.14.1. Company Overview 23
         10.14.2. Financial Performance 23
         10.14.3. Product Benchmarking 23
         10.15.1. Company Overview 23
        10.15.2. Financial Performance 23
        10.15.3. Product Benchmarking 23
        10.16.1. Company Overview 23
        10.16.2. Financial Performance 23
         10.16.3. Product Benchmarking 23
         10.17.1. Company Overview 24
         10.17.2. Financial Performance 24
         10.17.3. Product Benchmarking 24
         10.18.1. Company Overview 24
         10.18.2. Financial Performance 24
          10.18.3. Product Benchmarking 24
          10.19.1. Company Overview 24
          10.19.2. Financial Performance 24
          10.19.3. Product Benchmarking 24
          10.20.1. Company Overview 24
          10.20.2. Financial Performance 24
          10.20.3. Product Benchmarking 24

TABLE # 1 GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET BY APPLICATION 2012-2022 ($ BILLION) 25
TABLE # 2 GLOBAL DIAGNOSTIC DEVELOPMENT MARKET 2012-2022 ($ BILLION) 25
TABLE # 3 GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET 2012-2022 ($ BILLION) 25
TABLE # 4 GLOBAL PERSONALIZED MEDICINE MARKET 2012-2022 ($ BILLION) 26
TABLE # 5 GLOBAL DISEASE RISK ASSESSMENT MARKET 2012-2022 ($ BILLION) 26
TABLE # 6 5.1.1.5. GLOBAL OTHER MARKET 2012-2022 ($ BILLION) 26
TABLE # 7 GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET BY END USER 2012-2022 ($ BILLION) 26
TABLE # 8 GLOBAL HOSPITAL MARKET 2012-2022 ($ BILLION) 26
TABLE # 9 GLOBAL EYE CLINICS MARKET 2012-2022 ($ BILLION) 26
TABLE # 10 GLOBAL DIAGNOSTIC CENTERS MARKET 2012-2022 ($ BILLION) 26
TABLE # 11 GLOBAL PATIENTS MARKET 2012-2022 ($ BILLION) 26
TABLE # 12 GLOBAL OTHER MARKET 2012-2022 ($ BILLION) 26
TABLE # 13 26
TABLE # 14 GLOBAL CENTRAL NERVOUS SYSTEM(CNS) BIOMARKERS MARKET, BY TYPE, 2015-2022($ BILLION) 26
TABLE # 15 5.1.2.1. GLOBAL SAFETY BIOMARKER MARKET 2012-2022 ($ BILLION) 26
TABLE # 16 5.1.2.2. GLOBAL EFFICACY BIOMARKER MARKET 2012-2022 ($ BILLION) 26
TABLE # 17 5.1.2.2.1. GLOBAL PREDICTIVE BIOMARKER MARKET 2012-2022 ($ BILLION) 2012-2022 ($ BILLION) 26
TABLE # 18 5.1.2.2.2. GLOBAL PHARMACODYNAMIC BIOMARKER MARKET 2012-2022 ($ BILLION) 26
TABLE # 19 5.1.2.2.3. GLOBAL PROGNOSTIC BIOMARKER MARKET 2012-2022 ($ BILLION) 26
TABLE # 20 5.1.2.3. GLOBAL VALIDATION BIOMARKER MARKET 2012-2022 ($ BILLION) 26

FIGURE # 1 MARKET SHARE BY REGIONS 27
FIGURE # 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
FIGURE # 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
FIGURE # 4 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
FIGURE # 5 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
FIGURE # 6 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
FIGURE # 7 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
FIGURE # 8 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
FIGURE # 9 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
FIGURE # 10 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
FIGURE # 11 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
FIGURE # 12 CENTRAL & SOUTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
FIGURE # 13 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)